BCTX BriaCell Therapeutics Corp.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1610820 · Fiscal year ends 07/31
Financial factors as of 2026-07-31 (2026Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.7%
TTM EPS YoY88.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-203.6%
ROA-154.3%
ROIC (approx.)-408.8%
Asset turnover—
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio2.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.82x
Accruals ratio-27.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-07-31 | FY20252025-07-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $29.24M | $21.27M |
| SG&A expense | $6.82M | $5.93M |
| Operating income | -$36.05M | -$27.20M |
| Interest expense | $29,631 | $36,979 |
| Pretax income | $35.33M | $26.56M |
| Net income | -$34.90M | -$26.31M |
| EBITDA | -$35.95M | -$27.11M |
| EPS (basic) | -6.97 | -62.19 |
| EPS (diluted) | -6.97 | -62.19 |
| Weighted avg. shares (diluted) | 5.01M | 423,114 |
| Balance sheet | ||
| Cash & equivalents | $9.85M | $10.49M |
| Short-term investments | $10.69M | $7.37M |
| Current assets | $22.04M | $19.93M |
| PP&E, net | $319,804 | $296,819 |
| Intangibles | $169,254 | $184,525 |
| Total assets | $23.58M | $21.65M |
| Current liabilities | $7.98M | $3.98M |
| Total liabilities | $8.02M | $4.32M |
| Shareholders' equity | $16.40M | $17.88M |
| Shares outstanding | 8.71M | 1.88M |
| Cash flow statement | ||
| Operating cash flow | -$28.65M | -$28.17M |
| Capital expenditure | $127,049 | — |
| Free cash flow | -$28.78M | — |
| Investing cash flow | -$3.81M | -$7.65M |
| Financing cash flow | $31.81M | $45.45M |
| Depreciation & amortization | $104,064 | $91,356 |
| Stock-based compensation | $1.13M | $656,829 |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.